01:25 PM EDT, 07/25/2024 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Thursday it received a label expansion approval from the US Food and Drug Administration for its oral treatment Livmarli for progressive familial intrahepatic cholestasis in patients 12 months and older.

The company said the expanded label also includes a higher concentration formulation of Livmarli, which was evaluated in a phase 3 study.

Shares of Mirum rose 6.3% in recent trading.

Price: 41.52, Change: +2.45, Percent Change: +6.27